Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Sutro Biopharma Inc STRO

Healthcare Biotechnology
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:STRO)

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

GlobeNewswire April 2, 2024

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire March 25, 2024

Sutro Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire February 6, 2024

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

GlobeNewswire January 4, 2024

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

GlobeNewswire December 14, 2023

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

GlobeNewswire December 11, 2023

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire December 4, 2023

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

GlobeNewswire November 27, 2023

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

GlobeNewswire November 21, 2023
View More News ››

Opinion & Analysis (NDAQ:STRO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:STRO)

4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION!

$STRO $MTEM $SNDX $KRYS Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of...
AviseAnalytics - October 5, 2021
View more Bullboard ››

Hillcrest Energy Technologies Ltd.

Hillcrest Energy Technologies Ltd.

Hillcrest Energy Technologies is a clean tech innovation company developing high value, high-performance control systems and ...
View More »